The goal is to combine the accuracy of SunTech’s Advantage cuff-based blood pressure technology, and its TMT (Transport Motion Tolerance) capabilities, with continuous BP estimation from Valencell’s optical PPG (photoplethysmography) technology, in order to provide a new and better BP measurement solution for higher acuity market segments like hemodialysis, emergency medicine, OR and ICU, ambulatory BP studies and cardiac rehabilitation, and sleep.
This multi-year agreement will allow the companies to work together to develop customized solutions and products for other medical device OEMs, as well as allowing SunTech to incorporate Valencell technology in its finished, branded products.
A Multi-Year Partnership
“The combination of multiple motion-tolerant technologies and measurement modalities from SunTech and Valencell will enable comfortable, continuous, clinical-grade BP monitoring for many applications,” said Paul Matsumura, SunTech’s senior director of Research and Technology about how the technologies could work in concert. “SunTech and Valencell are each the best in their field of motion tolerant blood pressure and PPG technology, respectively. Both together is a winning combination in the clinical space,” said Julian Mullaney, SunTech’s vice president of R&D about the deal.
Dr. Steven LeBeouf, Valencell’s president and co-founder, had this to say about the multi-year collaboration agreement: “SunTech Medical is a universally respected industry leader in clinical-grade BP solutions, and their expertise in this area has been clear from the very beginning of our work together. We are extremely happy to be working with SunTech to bring new technologies and capabilities to market together for the clinical sector and for patients around the world. Our two companies have identified critical medical use cases that can only be effectively addressed by combining Valencell’s deep-PPG technology with SunTech’s motion-tolerant blood pressure technology.”
The collaboration agreement was signed in conjunction with an investment in Valencell by SunTech Medical’s parent corporation, Halma plc.
Kent Novak, Valencell’s CEO, had this to say about the agreement: “This collaboration agreement with SunTech sets the stage for some very exciting work together. Our teams each bring tremendous experience, expertise and technology from our respective domains. Establishing this long-term agreement with SunTech helps accelerate the joint innovations that will have meaningful impacts on the market and more importantly on patient outcomes.”